NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
20 trialsNCT04904302 2026-03-16
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05846646 2025-10-20
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT02446860 2025-06-06
ADAPTeR
Royal Marsden NHS Foundation Trust
Phase 2 Terminated
NCT06884683 2025-03-19
NivoMet
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Terminated
NCT03991130 2025-02-06
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
Phase 2 Terminated
NCT06034860 2024-11-01
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
Phase 1 Terminated
NCT03552380 2024-09-03
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03562507 2024-05-20
ERICA
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT04429321 2024-04-26
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT03311334 2024-04-18
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT04300140 2023-10-30
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Aravive, Inc.
Phase 1/2 Terminated
NCT03729245 2023-04-11
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
Phase 3 Terminated
NCT03435640 2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2 Terminated
NCT04088500 2023-01-10
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
Bristol-Myers Squibb
Phase 2 Terminated
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT03655613 2022-05-06
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Apollomics (Australia) Pty. Ltd.
Phase 1/2 Terminated
NCT02959554 2021-09-08
NIVOSWITCH
AIO-Studien-gGmbH
Phase 2 Terminated
NCT02595918 2020-10-23
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT02423954 2018-07-02
NivoPlus
Western Regional Medical Center
Phase 1/2 Terminated